We were proud to take part in the official launch of the 2025 Catalyser programme last Thursday at Stevenage Bioscience Catalyst!
May 19, 2025
Pharmidex is excited to support this incredible initiative, which welcomes 8 promising therapeutics companies at (or near) the pre-clinical stage.
Over the next 8 weeks, they’ll sharpen their strategy using the Triple Chasm framework and gain access to a powerful mix of scientific, business, and communication support.
During the launch, our very own
Ash Alavijeh joined
Prabhu Velusami, MD (Johnson & Johnson) and
Daniel Marshall (MSD) in a panel discussion exploring trends and opportunities in the therapeutics landscape.
It was a brilliant exchange of insights that inspired the cohort and sparked new conversations.
As part of the Catalyser package, we’re proud to offer:
🔬 Complimentary CRO services from Pharmidex
🤖 AI innovation support with Asae Biotechnology Consulting
🎤 1:1 storytelling coaching with
Kat Arney
from First Create The Media
Huge thanks to Hertfordshire Futures and Stevenage Bioscience Catalyst for driving this programme and for the opportunity to collaborate with such a forward-thinking ecosystem!
At Pharmidex , we help drug developers move faster and smarter with high-quality PK/PD assessments and bioanalytical services across a range of therapeutic areas. 🔬 Our team combines: Bespoke In vivo PK/PD & CNS penetration studies Wild-type, immunodeficient & humanised rodent models Advanced platforms: LC-MS/MS, qPCR, ELISA 🧠 Whether you're working on CNS drugs, oncology assets, or rare disease therapies, we deliver high quality data to drive confident decisions from lead optimisation to IND-enabling studies. ✨ Need to evaluate: BBB penetration? Target tissue exposure? PK profiling of small molecules or biologics? We’ve got you covered. 📨 Let’s talk see how Pharmidex can support your next breakthrough: 🌐 www.pharmidex.com
Since 2002, Pharmidex has grown into a trusted partner in preclinical drug discovery and development, contributing to over 16,000 studies across therapeutic areas including CNS, immunology, oncology, respiratory and stroke. We’re proud to be AAALAC- and MHRA-accredited, providing high-quality GLP and GCP-compliant services that have supported clients across biotech, pharma, and academia worldwide. Our integrated expertise in Clinical Pathology, DMPK, ADMET, Pharmacokinetics, Toxicology and BBB penetration studies continues to shape the success of early-stage drug candidates. 💡 As we commemorate this milestone, we reflect on: ✔ The dedication of our exceptional team ✔ The trust and collaboration of our partners and clients ✔ Our continued mission to advance science and improve lives Here’s to 23 years of impact and many more to come!
At Pharmidex, we are proud to contribute to scientific innovation through robust and reliable bioanalytical support from early discovery to regulated studies. For over eight years, we've partnered with Shimadzu, using their LCMS-8060 and LC-2050 systems to deliver high-quality, data-driven results tailored to diverse client needs. Their instruments have played a key role in advancing our bioanalytical capabilities and supporting the success of our collaborative projects. Our Head of Operations, Ash Alavijeh , recently shared insights from our long-standing collaboration as part of Shimadzu’s 150th anniversary testimonial series. We are honored to be part of their journey and look forward to continuing this partnership built on shared values of precision, reliability, and innovation. 👉 Read more stories from the Shimadzu global community here .
